Circulating microRNAs as novel biomarkers for diabetes mellitus
Measuring circulating levels of microRNAs is a promising strategy for identifying people at risk of developing diabetes mellitus; however, several obstacles still need to be overcome before this strategy can be used in clinical practice. This Review summarizes the weaknesses of current biomarkers an...
Saved in:
| Published in: | Nature reviews. Endocrinology Vol. 9; no. 9; pp. 513 - 521 |
|---|---|
| Main Authors: | , |
| Format: | Journal Article |
| Language: | English |
| Published: |
London
Nature Publishing Group UK
01-09-2013
Nature Publishing Group |
| Subjects: | |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Measuring circulating levels of microRNAs is a promising strategy for identifying people at risk of developing diabetes mellitus; however, several obstacles still need to be overcome before this strategy can be used in clinical practice. This Review summarizes the weaknesses of current biomarkers and discusses the potential use of microRNAs as novel biomarkers.
Diabetes mellitus is characterized by insulin secretion from pancreatic β cells that is insufficient to maintain blood glucose homeostasis. Autoimmune destruction of β cells results in type 1 diabetes mellitus, whereas conditions that reduce insulin sensitivity and negatively affect β-cell activities result in type 2 diabetes mellitus. Without proper management, patients with diabetes mellitus develop serious complications that reduce their quality of life and life expectancy. Biomarkers for early detection of the disease and identification of individuals at risk of developing complications would greatly improve the care of these patients. Small non-coding RNAs called microRNAs (miRNAs) control gene expression and participate in many physiopathological processes. Hundreds of miRNAs are actively or passively released in the circulation and can be used to evaluate health status and disease progression. Both type 1 diabetes mellitus and type 2 diabetes mellitus are associated with distinct modifications in the profile of miRNAs in the blood, which are sometimes detectable several years before the disease manifests. Moreover, circulating levels of certain miRNAs seem to be predictive of long-term complications. Technical and scientific obstacles still exist that need to be overcome, but circulating miRNAs might soon become part of the diagnostic arsenal to identify individuals at risk of developing diabetes mellitus and its devastating complications.
Key Points
New biomarkers are needed to improve the identification of individuals at risk of developing diabetes mellitus and its associated complications, monitor disease progression and assess the efficacy of therapeutic interventions
Circulating microRNAs (miRNAs) are attractive biomarker candidates as they can be easily collected, are stable under different storage conditions and can be measured using assays that are specific, sensitive and reproducible
Pioneering studies have identified characteristic changes in blood levels of miRNAs in samples from a range of cohorts of patients with diabetes mellitus
However, definitive miRNA signatures for type 1 diabetes mellitus, type 2 diabetes mellitus or their associated complications remain to be defined and agreed upon
Although measuring circulating miRNAs is a promising approach in individuals at risk of developing diabetes mellitus, several key issues still need to be addressed, including the determination of the most appropriate blood sampling protocols |
|---|---|
| Bibliography: | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-3 content type line 23 ObjectType-Review-1 |
| ISSN: | 1759-5029 1759-5037 |
| DOI: | 10.1038/nrendo.2013.86 |